Cargando…
Eritoran insight for influenza treatment
A University of Maryland team has used a toll-like receptor 4 antagonist to treat influenza in mice. The results provide a repurposing opportunity for Eisai's TLR4 blocker Eritoran, originally developed for sepsis and could extend to treating respiratory infections beyond the flu.
Autor principal: | Baas, Tracey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149081/ http://dx.doi.org/10.1038/scibx.2013.453 |
Ejemplares similares
-
Eritoran: the evidence of its therapeutic potential in sepsis
por: Raja, Shahzad G., et al.
Publicado: (2007) -
Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury
por: Hsieh, Yun-Cheng, et al.
Publicado: (2021) -
The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge
por: Younan, Patrick, et al.
Publicado: (2017) -
0986. The effect of eritoran on the severity of lung injury in two different rat lung injury models
por: Kundakci, A, et al.
Publicado: (2014) -
Evaluation of eritoran tetrasodium (E5564), a TLR4 antagonist, on the QTc interval in healthy subjects
por: Nagy, CF, et al.
Publicado: (2011)